在患有亚托皮性皮肤炎的患者中,特拉洛金纽马布诱导的矛盾牛皮
Galina Balakirski1, Sven-Niklas Burmann2, Silke C Hofmann1
1Center for Dermatology, Allergology and Dermatosurgery, Helios University Hospital Wuppertal, University of Witten/Herdecke, Wuppertal, Germany.
The Journal of dermatological treatment
|September 14, 2023
概括
选择性IL-13抑制与tralokinumab在一个患者的亚托皮性皮肤炎 (AD) 悖论诱导的牛皮. 这表明单独准IL-13可以将免疫反应转向IL-17介导的疾病.
科学领域:
- 免疫皮肤学 免疫皮肤学
- 皮肤病学中的生物学物质.
- 细胞因子通路研究研究
背景情况:
- 牛皮和亚托邦性皮肤炎 (AD) 在历史上被视为相反的疾病,但现在可以理解它们是共存的.
- 向免疫疗法,特别是介质素 (IL) 抑制剂,可以破坏Th1和Th2免疫之间的平衡.
- 与抗TNF-alpha,抗IL-23和抗IL-17疗法观察到矛盾的牛皮,而双 IL-4 / IL-13 阻塞 (dupilumab) 可以诱导AD.
相关概念视频
Antiasthma Drugs: Leukotriene Modifiers
343
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
343
T Cell Types and Functions
1.1K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.1K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
168
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
168
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
190
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
190
Psychosis: Goals of Pharmacotherapy
165
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
165
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
332
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
332


